Tissue Factor: Old and New Links with Cancer Biology

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 7, 2015, Pages 747-755

  Versteeg, Henri H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

blood clotting; integrins; protease activated receptors; stem cells; tumor biology

Indexed keywords

THROMBOPLASTIN; ISOPROTEIN; TUMOR PROTEIN;

ALTERNATIVE RNA SPLICING; BLOOD CLOTTING; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CONFERENCE PAPER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR CELL; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ALTERNATIVE SPLICING; ANIMALS; BLOOD COAGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; STEM CELL NICHE; THROMBOPLASTIN; TUMOR MICROENVIRONMENT;

EID: 84943647511     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1556048     Document Type: Conference Paper

References (78)

1. Timp J. F., Braekkan S. K., Versteeg H. H., Cannegieter S. C. Epidemiology of cancer-associated venous thrombosis. Blood: 2013; 122 10 1712 1723
2. Lyman G. H., Khorana A. A. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol: 2009; 27 29 4821 4826
3. Klerk C. PW, Smorenburg S. M., Otten H-M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol: 2005; 23 10 2130 2135
4. Lee A. YY, Rickles F. R., Julian J. A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol: 2005; 23 10 2123 2129
5. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med: 2000; 342 26 1953 1958
6. Pengo V., Noventa F., Denas G., et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood: 2011; 117 5 1707 1709
7. van den Berg Y. W., Osanto S., Reitsma P. H., Versteeg H. H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood: 2012; 119 4 924 932
8. Versteeg H. H., Heemskerk J. WM, Levi M., Reitsma P. H. New fundamentals in hemostasis. Physiol Rev: 2013; 93 1 327 358
9. Ünlü B., Versteeg H. H. Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? Thromb Res: 2014; 133 02 S76 S84
10. Vu T. K., Hung D. T., Wheaton V. I., Coughlin S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell: 1991; 64 6 1057 1068
11. Riewald M., Petrovan R. J., Donner A., Mueller B. M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science: 2002; 296 5574 1880 1882
12. Nakanishi-Matsui M., Zheng Y. W., Sulciner D. J., Weiss E. J., Ludeman M. J., Coughlin S. R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature: 2000; 404 6778 609 613
13. Bretschneider E., Spanbroek R., Lötzer K., Habenicht A. JR, Schrör K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost: 2003; 90 4 704 709
14. Bazan J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A: 1990; 87 18 6934 6938
15. Camerer E., Huang W., Coughlin S. R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A: 2000; 97 10 5255 5260
16. Camerer E., Rottingen J. A., Iversen J. G., Prydz H. Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem: 1996; 271 46 29034 29042
17. Versteeg H. H., Hoedemaeker I., Diks S. H., et al. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem: 2000; 275 37 28750 28756
18. Versteeg H. H., Bresser H. L., Spek C. A., Richel D. J., Van Deventer S. J., Peppelenbosch M. P. Regulation of the p21Ras-MAP kinase pathway by factor VIIa. J Thromb Haemost: 2003; 1 5 1012 1018
19. Camerer E., Gjernes E., Wiiger M., Pringle S., Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem: 2000; 275 9 6580 6585
20. Versteeg H. H., Sorensen B. B., Slofstra S. H., et al. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. J Biol Chem: 2002; 277 30 27065 27072
21. Versteeg H. H., Spek C. A., Richel D. J., Peppelenbosch M. P. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene: 2004; 23 2 410 417
22. Ahamed J., Versteeg H. H., Kerver M., et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A: 2006; 103 38 13932 13937
23. Reinhardt C., von Brühl M-L, Manukyan D., et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest: 2008; 118 3 1110 1122
24. Versteeg H. H., Schaffner F., Kerver M., et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood: 2008; 111 1 190 199
25. Dorfleutner A., Hintermann E., Tarui T., Takada Y., Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell: 2004; 15 10 4416 4425
26. Belting M., Dorrell M. I., Sandgren S., et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med: 2004; 10 5 502 509
27. Collier M. EW, Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol: 2010; 30 9 1810 1817
28. Collier M. EW, Li C., Ettelaie C. Influence of exogenous tissue factor on estrogen receptor alpha expression in breast cancer cells: involvement of beta1-integrin, PAR2, and mitogen-activated protein kinase activation. Mol Cancer Res: 2008; 6 12 1807 1818
29. Arderiu G., Peña E., Aledo R., Juan-Babot O., Badimon L. Tissue factor regulates microvessel formation and stabilization by induction of chemokine (C-C motif) ligand 2 expression. Arterioscler Thromb Vasc Biol: 2011; 31 11 2607 2615
30. Arderiu G., Peña E., Aledo R., Badimon L. Tissue factor-Akt signaling triggers microvessel formation. J Thromb Haemost: 2012; 10 9 1895 1905
31. Yu J. L., May L., Lhotak V., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood: 2005; 105 4 1734 1741
32. Magnus N., Garnier D., Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood: 2010; 116 5 815 818
33. Rong Y., Post D. E., Pieper R. O., Durden D. L., Van Meir E. G., Brat D. J. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res: 2005; 65 4 1406 1413
34. Sun L., Liu Y., Lin S., et al. Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor. Acta Oncol: 2013; 52 4 842 851
35. Gessler F., Voss V., Dützmann S., Seifert V., Gerlach R., Kögel D. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience: 2010; 165 4 1312 1322
36. Yokota N., Koizume S., Miyagi E., et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer: 2009; 101 12 2023 2029
37. Kakkar A. K., Lemoine N. R., Scully M. F., Tebbutt S., Williamson R. C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg: 1995; 82 8 1101 1104
38. Rydén L., Grabau D., Schaffner F., Jönsson P. E., Ruf W., Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer: 2010; 126 10 2330 2340
39. Shigemori C., Wada H., Matsumoto K., Shiku H., Nakamura S., Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost: 1998; 80 6 894 898
40. Kocatürk B., Van den Berg Y. W., Tieken C., et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A: 2013; 110 28 11517 11522
41. Yeh H-H, Chang W-T, Lu K-C, Lai W. W., Liu H. S., Su W. C. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma. PLoS ONE: 2013; 8 9 e75287
42. Song H. B., Park K. D., Kim J. H., Kim D. H., Yu Y. S., Kim J. H. Tissue factor regulates tumor angiogenesis of retinoblastoma via the extracellular signal-regulated kinase pathway. Oncol Rep: 2012; 28 6 2057 2062
43. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest: 1994; 94 3 1320 1327
44. Versteeg H. H., Spek C. A., Slofstra S. H., Diks S. H., Richel D. J., Peppelenbosch M. P. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res: 2004; 94 8 1032 1040
45. Abe K., Shoji M., Chen J., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A: 1999; 96 15 8663 8668
46. Versteeg H. H., Schaffner F., Kerver M., et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res: 2008; 68 17 7219 7227
47. Milsom C. C., Yu J. L., Mackman N., et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res: 2008; 68 24 10068 10076
48. Saito Y., Hashimoto Y., Kuroda J., et al. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer: 2011; 47 14 2230 2239
49. Schaffner F., Versteeg H. H., Schillert A., et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood: 2010; 116 26 6106 6113
50. Yu J., May L., Milsom C., et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol: 2008; 28 11 1975 1981
51. Zhang J-Q, Wan Y-L, Liu Y-C., et al. The FVIIa-tissue factor complex induces the expression of MMP7 in LOVO cells in vitro. Int J Colorectal Dis: 2008; 23 10 971 978
52. Lin Z-M, Zhao J-X, Duan X-N., et al. Effects of tissue factor, PAR-2 and MMP-9 expression on human breast cancer cell line MCF-7 invasion. Asian Pac J Cancer Prev: 2014; 15 2 643 646
53. Tian M., Wan Y., Tang J., et al. Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther: 2011; 12 10 896 907
54. Conn E. M., Madsen M. A., Cravatt B. F., Ruf W., Deryugina E. I., Quigley J. P. Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation. J Biol Chem: 2008; 283 39 26518 26527
55. Morris D. R., Ding Y., Ricks T. K., Gullapalli A., Wolfe B. L., Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res: 2006; 66 1 307 314
56. Fischer E. G., Riewald M., Huang H. Y., et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest: 1999; 104 9 1213 1221
57. Seto S., Onodera H., Kaido T., et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer: 2000; 88 2 295 301
58. Palumbo J. S., Talmage K. E., Massari J. V., et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood: 2007; 110 1 133 141
59. Brüggemann L. W., Versteeg H. H., Niers T. M., Reitsma P. H., Spek C. A. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med: 2008; 12 (6B): 2622 2627
60. Palumbo J. S., Talmage K. E., Massari J. V., et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood: 2005; 105 1 178 185
61. Gil-Bernabé A. M., Ferjancic S., Tlalka M., et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood: 2012; 119 13 3164 3175
62. Findlay V. J., Wang C., Watson D. K., Camp E. R. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther: 2014; 21 5 181 187
63. Mallini P., Lennard T., Kirby J., Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev: 2014; 40 3 341 348
64. Milsom C., Anderson G. M., Weitz J. I., Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost: 2007; 5 12 2550 2552
65. Magnus N., Garnier D., Meehan B., et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A: 2014; 111 9 3544 3549
66. Peña E., Arderiu G., Badimon L. Tissue factor induces human coronary artery smooth muscle cell motility through Wnt-signalling. J Thromb Haemost: 2013; 11 10 1880 1891
67. Schaffner F., Yokota N., Carneiro-Lobo T., et al. Endothelial protein C receptor function in murine and human breast cancer development. PLoS ONE: 2013; 8 4 e61071
68. Slatter T. L., Hung N., Campbell H., et al. Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood: 2011; 117 19 5166 5177
69. Pabla N., Bhatt K., Dong Z. Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc Natl Acad Sci U S A: 2012; 109 1 197 202
70. Nowak D. G., Woolard J., Amin E. M., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci: 2008; 121 Pt 20 3487 3495
71. Cáceres J. F., Kornblihtt A. R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet: 2002; 18 4 186 193
72. Chandradas S., Deikus G., Tardos J. G., Bogdanov V. Y. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. J Leukoc Biol: 2010; 87 1 147 152
73. Eisenreich A., Bogdanov V. Y., Zakrzewicz A., et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res: 2009; 104 5 589 599
74. Eisenreich A., Malz R., Pepke W., et al. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J: 2009; 73 9 1746 1752
75. Bogdanov V. Y., Balasubramanian V., Hathcock J., Vele O., Lieb M., Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med: 2003; 9 4 458 462
76. Rollin J., Regina S., Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost: 2010; 8 3 607 610
77. Unruh D., Turner K., Srinivasan R., et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer: 2014; 134 1 9 20
78. van den Berg Y. W., van den Hengel L. G., Myers H. R., et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A: 2009; 106 46 19497 19502